Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy]
2011

Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost

Sample size: 49 publication Evidence: moderate

Author Information

Author(s): Jensen Alexandra D, Nikoghosyan Anna, Hinke Axel, Debus Jürgen, Münter Marc W

Primary Institution: Dept. of Radiation Oncology, University of Heidelberg

Hypothesis

The combination of IMRT and carbon ion boost with cetuximab will improve local control in patients with adenoid cystic carcinoma.

Conclusion

The ACCEPT trial aims to evaluate the toxicity and feasibility of combining cetuximab with advanced radiation therapy techniques for treating adenoid cystic carcinoma.

Supporting Evidence

  • Local control rates in adenoid cystic carcinoma could be improved with advanced radiation techniques.
  • Cetuximab has shown promise in enhancing the effects of radiation therapy.

Takeaway

This study is testing a new way to treat a rare type of cancer using a special medicine and advanced radiation to see if it works better than current methods.

Methodology

A prospective, mono-centric, phase I/II trial evaluating toxicity and efficacy of combined treatment with IMRT/carbon ion boost and weekly cetuximab in 49 patients.

Limitations

The study is limited to a specific patient population and may not be generalizable to all adenoid cystic carcinoma cases.

Participant Demographics

Patients aged 18 to 70 with histologically proven adenoid cystic carcinoma.

Digital Object Identifier (DOI)

10.1186/1471-2407-11-70

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication